<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02673515</url>
  </required_header>
  <id_info>
    <org_study_id>HS-2014-03</org_study_id>
    <nct_id>NCT02673515</nct_id>
  </id_info>
  <brief_title>The Impact of Intermittent Fasting on Human Metabolism and Cell Autophagy</brief_title>
  <acronym>InterFast</acronym>
  <official_title>The Impact of Intermittent Fasting on Human Metabolism and Cell Autophagy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Graz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Graz</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      InterFast is a Cohort study with an embedded randomized controlled pilot trial. Study
      participants will be healthy subjects and subjects who already practice Alternate Day
      Fasting. The trial will include 100 participants (50 Participants in Alternate Day Fasting
      group and 50 participants in the control group). Those participants in the control group will
      be asked to participate in a short randomized controlled trial, where they will be either
      allocated to an Alternative Day Fasting group or another control visit.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intermittent fasting is a dietary regimen defined by alternating fasting and &quot;feeding&quot;
      cycles. In addition to caloric restriction (a dietary regimen limited to a daily food intake
      lower than one's daily caloric needs) only, intermittent fasting seems to activate cell
      autophagy (cellular &quot;recycling&quot; program) which potentially increases cellular stress
      resistance and removes accumulated molecules that are potentially toxic. In fact, mice
      maintained on intermittent fasting without decreased overall food intake show effects on body
      weight reduction that equal and in some cases even exceed those of calorie restriction.
      However, additionally, intermittent fasting combined with even a high-fat diet in the feeding
      periods protects mice from obesity, hyperinsulinemia, hepatic steatosis, and inﬂammation
      compared to controls that are fed an ad libitum high-fat diet despite the same calorie
      intake, making this intermittent fasting regimen a promising approach to reduce morbidity and
      mortality in various species.

      The best described and most widely practiced version of intermittent fasting is the
      &quot;alternate day diet&quot; or &quot;alternate day fasting&quot; (ADF). In animal models, ADF consists of an
      ad libitum &quot;feed day&quot; alternated with a 100% restriction &quot;fast day&quot;. However in humans, this
      is often modified to allow a small amount of food consumption on the &quot;fast day&quot; (e.g. 25% of
      the individual´s energy needs). Findings from recent modified ADF studies showed significant
      reductions in body weight.

      However, knowledge about the molecular effects of the alternate day diet on human metabolism
      or autophagy is still scarce since detailed analyses of molecular and metabolic parameters
      remain unexplored, especially in healthy individuals. The overarching aim of this research
      project is to elucidate in which extent alternate day fasting (and thereby intermittent
      fasting) influences human physiology in healthy individuals in both short and long term. The
      secondary objective of this study is to define novel molecular markers of aging and
      age-related diseases.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">September 2, 2019</completion_date>
  <primary_completion_date type="Actual">September 2, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin Sensitivity (HOMA-IR)</measure>
    <time_frame>4 weeks (from Baseline to 4 weeks)</time_frame>
    <description>HOMA-Index was calculated by using the following formula:
HOMA-IR= FPG(mmol/l)*FSI (U/l)/22.5 FSI=fasting serum insulin FPG=fasting plasma glucose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin Sensitivity (QUICKI)</measure>
    <time_frame>4 weeks (from Baseline to 4 weeks)</time_frame>
    <description>QUICKI was calculated by using the following formula: QUICKI= log(FSI)+log (FPG) FSI=fasting serum insulin FPG=fasting plasma glucose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin Sensitivity (ISI-Index)</measure>
    <time_frame>4 weeks (from Baseline to 4 weeks)</time_frame>
    <description>ISI was calculated by using the following formula: ISI=0,222−0,00333 x BMI−0,0000779 x Ins120−0,000422 x age FSI=fasting serum insulin FPG=fasting plasma glucose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin Sensitivity (Matsuda-Index)</measure>
    <time_frame>4 weeks (from Baseline to 4 weeks)</time_frame>
    <description>Matsuda index was calculated by using the following formula:
Matsuda-Index = 10000√(FPG∗FSI)∗(mean glucose*mean insulin) FSI=fasting serum insulin FPG=fasting plasma glucose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure (Systolic and Diastolic)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change of blood pressure from Baseline to 4 weeks</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Excessive Diet Restriction</condition>
  <arm_group>
    <arm_group_label>Alternate day fasting</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects are requested to alternate fast for 4 weeks (alternate an ad libitum &quot;feed day&quot; with a 100% restriction &quot;fast day&quot;).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>control group</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Alternate day fasting</intervention_name>
    <description>Subjects are requested to fast every other day. Calorie free fluids are allowed.</description>
    <arm_group_label>Alternate day fasting</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index in the range of 22.0 - 27.0 kg/m2,

          -  Fasting blood glucose &lt;110mg/dL (without medication)

          -  LDL-cholesterol &lt;180 mg/dL (without medication)

          -  Blood pressure &lt;140/90 mmHg (without medication)

          -  Stable weight (change &lt;± 10%) for 3 months immediately prior to the study,

          -  No history of metabolic disorders or cardiovascular disease

          -  No acute or chronic inflammatory disorder

          -  No current medications to regulate blood sugar, blood pressure or lipids or hormones

          -  No heavy drinking (more than 15 drinks/week)

          -  No use of tobacco or recreational drugs within past 5 years

          -  No dietary restrictions (e.g. vegetarianism and vegan)

        Exclusion Criteria:

          -  Known Malignancy

          -  Women who are pregnant, breast-feeding or trying to become pregnant

          -  History of any chronic disease process that could interfere with interpretation of
             study results

          -  Women or men on hormonal supplementation or anti-conceptive hormonal medication for at
             least 2 months

          -  Therapy with antidepressants within past 6 months

          -  Regular therapy with acetylsalicylic acid
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harald Sourij, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Graz, Auenbruggerplatz 15</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frank Madeo, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Karl Franzens University Graz, Austria</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas R Pieber, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Medical University Graz, Austria</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept. of Internal Medicine, Medical University of Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <reference>
    <citation>Tripolt NJ, Stekovic S, Aberer F, Url J, Pferschy PN, Schröder S, Verheyen N, Schmidt A, Kolesnik E, Narath SH, Riedl R, Obermayer-Pietsch B, Pieber TR, Madeo F, Sourij H. Intermittent Fasting (Alternate Day Fasting) in Healthy, Non-obese Adults: Protocol for a Cohort Trial with an Embedded Randomized Controlled Pilot Trial. Adv Ther. 2018 Aug;35(8):1265-1283. doi: 10.1007/s12325-018-0746-5. Epub 2018 Jul 25.</citation>
    <PMID>30046988</PMID>
  </reference>
  <results_reference>
    <citation>Stekovic S, Hofer SJ, Tripolt N, Aon MA, Royer P, Pein L, Stadler JT, Pendl T, Prietl B, Url J, Schroeder S, Tadic J, Eisenberg T, Magnes C, Stumpe M, Zuegner E, Bordag N, Riedl R, Schmidt A, Kolesnik E, Verheyen N, Springer A, Madl T, Sinner F, de Cabo R, Kroemer G, Obermayer-Pietsch B, Dengjel J, Sourij H, Pieber TR, Madeo F. Alternate Day Fasting Improves Physiological and Molecular Markers of Aging in Healthy, Non-obese Humans. Cell Metab. 2019 Sep 3;30(3):462-476.e6. doi: 10.1016/j.cmet.2019.07.016. Epub 2019 Aug 27. Erratum in: Cell Metab. 2020 Apr 7;31(4):878-881.</citation>
    <PMID>31471173</PMID>
  </results_reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>November 24, 2015</study_first_submitted>
  <study_first_submitted_qc>February 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2016</study_first_posted>
  <results_first_submitted>March 23, 2020</results_first_submitted>
  <results_first_submitted_qc>May 14, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">May 28, 2020</results_first_posted>
  <last_update_submitted>May 14, 2020</last_update_submitted>
  <last_update_submitted_qc>May 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alternate Day Fasting</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 1, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/15/NCT02673515/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>After interviewing 462 adults for study eligibility based on previously set inclusion and exclusion criteria we have selected 60 representative study participants for the randomized controlled trial.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Alternate Day Fasting</title>
          <description>Subjects are requested to alternate fast for 4 weeks (alternate an ad libitum “feed day” with a 100% restriction “fast day”).
Alternate day fasting: Subjects are requested to fast every other day. Calorie free fluids are allowed.</description>
        </group>
        <group group_id="P2">
          <title>Control Group</title>
          <description>participants in the control group should be remaining on their usual diet</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of motivation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Alternate Day Fasting</title>
          <description>Subjects are requested to alternate fast for 4 weeks (alternate an ad libitum “feed day” with a 100% restriction “fast day”).
Alternate day fasting: Subjects are requested to fast every other day. Calorie free fluids are allowed.</description>
        </group>
        <group group_id="B2">
          <title>Control Group</title>
          <description>participants in the control group should be remaining on their usual diet</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                    <count group_id="B2" value="30"/>
                    <count group_id="B3" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48" lower_limit="42.5" upper_limit="55.0"/>
                    <measurement group_id="B2" value="50.5" lower_limit="44.5" upper_limit="56.75"/>
                    <measurement group_id="B3" value="49" lower_limit="43.25" upper_limit="55.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>per protocol analysis</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="28"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <population>per protocol analysis</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="28"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body weight</title>
          <population>per protocol analysis</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="28"/>
                    <count group_id="B2" value="29"/>
                    <count group_id="B3" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77.21" spread="10.25"/>
                    <measurement group_id="B2" value="75.93" spread="12.50"/>
                    <measurement group_id="B3" value="77.03" spread="11.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Insulin Sensitivity (HOMA-IR)</title>
        <description>HOMA-Index was calculated by using the following formula:
HOMA-IR= FPG(mmol/l)*FSI (U/l)/22.5 FSI=fasting serum insulin FPG=fasting plasma glucose</description>
        <time_frame>4 weeks (from Baseline to 4 weeks)</time_frame>
        <population>per protocol analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Alternate Day Fasting</title>
            <description>Subjects are requested to alternate fast for 4 weeks (alternate an ad libitum “feed day” with a 100% restriction “fast day”).
Alternate day fasting: Subjects are requested to fast every other day. Calorie free fluids are allowed.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>participants of the control group should be remaining on their usual diet</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Sensitivity (HOMA-IR)</title>
          <description>HOMA-Index was calculated by using the following formula:
HOMA-IR= FPG(mmol/l)*FSI (U/l)/22.5 FSI=fasting serum insulin FPG=fasting plasma glucose</description>
          <population>per protocol analysis</population>
          <units>no unit</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.95"/>
                    <measurement group_id="O2" value="0.06" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Insulin Sensitivity (QUICKI)</title>
        <description>QUICKI was calculated by using the following formula: QUICKI= log(FSI)+log (FPG) FSI=fasting serum insulin FPG=fasting plasma glucose</description>
        <time_frame>4 weeks (from Baseline to 4 weeks)</time_frame>
        <population>per protocol analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Alternate Day Fasting</title>
            <description>Subjects are requested to alternate fast for 4 weeks (alternate an ad libitum “feed day” with a 100% restriction “fast day”).
Alternate day fasting: Subjects are requested to fast every other day. Calorie free fluids are allowed.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>participants of the control group should be remaining on their usual diet</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Sensitivity (QUICKI)</title>
          <description>QUICKI was calculated by using the following formula: QUICKI= log(FSI)+log (FPG) FSI=fasting serum insulin FPG=fasting plasma glucose</description>
          <population>per protocol analysis</population>
          <units>no unit</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-0.02" upper_limit="0.02"/>
                    <measurement group_id="O2" value="0" lower_limit="-0.03" upper_limit="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Insulin Sensitivity (ISI-Index)</title>
        <description>ISI was calculated by using the following formula: ISI=0,222−0,00333 x BMI−0,0000779 x Ins120−0,000422 x age FSI=fasting serum insulin FPG=fasting plasma glucose</description>
        <time_frame>4 weeks (from Baseline to 4 weeks)</time_frame>
        <population>per protocol analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Alternate Day Fasting</title>
            <description>Subjects are requested to alternate fast for 4 weeks (alternate an ad libitum “feed day” with a 100% restriction “fast day”).
Alternate day fasting: Subjects are requested to fast every other day. Calorie free fluids are allowed.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>participants of the control group should be remaining on their usual diet</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Sensitivity (ISI-Index)</title>
          <description>ISI was calculated by using the following formula: ISI=0,222−0,00333 x BMI−0,0000779 x Ins120−0,000422 x age FSI=fasting serum insulin FPG=fasting plasma glucose</description>
          <population>per protocol analysis</population>
          <units>no unit</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0.01"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Insulin Sensitivity (Matsuda-Index)</title>
        <description>Matsuda index was calculated by using the following formula:
Matsuda-Index = 10000√(FPG∗FSI)∗(mean glucose*mean insulin) FSI=fasting serum insulin FPG=fasting plasma glucose</description>
        <time_frame>4 weeks (from Baseline to 4 weeks)</time_frame>
        <population>per protocol analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Alternate Day Fasting</title>
            <description>Subjects are requested to alternate fast for 4 weeks (alternate an ad libitum “feed day” with a 100% restriction “fast day”).
Alternate day fasting: Subjects are requested to fast every other day. Calorie free fluids are allowed.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>participants of the control group should be remaining on their usual diet</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Sensitivity (Matsuda-Index)</title>
          <description>Matsuda index was calculated by using the following formula:
Matsuda-Index = 10000√(FPG∗FSI)∗(mean glucose*mean insulin) FSI=fasting serum insulin FPG=fasting plasma glucose</description>
          <population>per protocol analysis</population>
          <units>no unit</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" lower_limit="-4.6" upper_limit="3.3"/>
                    <measurement group_id="O2" value="-0.7" lower_limit="-5.4" upper_limit="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of changes from baseline to 4 weeks between groups was tested with student´s t-test or Mann Whitney-U-Test</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.797</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Pressure (Systolic and Diastolic)</title>
        <description>Change of blood pressure from Baseline to 4 weeks</description>
        <time_frame>4 weeks</time_frame>
        <population>per protocol analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Alternate Day Fasting</title>
            <description>Subjects are requested to alternate fast for 4 weeks (alternate an ad libitum “feed day” with a 100% restriction “fast day”).
Alternate day fasting: Subjects are requested to fast every other day. Calorie free fluids are allowed.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>participants of the control group should be remaining on their usual diet</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Pressure (Systolic and Diastolic)</title>
          <description>Change of blood pressure from Baseline to 4 weeks</description>
          <population>per protocol analysis</population>
          <units>mmHg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systolic blood pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.5" lower_limit="-7.75" upper_limit="-0.5"/>
                    <measurement group_id="O2" value="-1" lower_limit="-6" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic blood pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" lower_limit="-4" upper_limit="1"/>
                    <measurement group_id="O2" value="0" lower_limit="-3.5" upper_limit="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During each study visit participants were asked about adverse events since the previous study visit. Adverse events were collected for 4 weeks (from study start to the end of the study).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Alternate Day Fasting</title>
          <description>Subjects are requested to alternate fast for 4 weeks (alternate an ad libitum “feed day” with a 100% restriction “fast day”).
Alternate day fasting: Subjects are requested to fast every other day. Calorie free fluids are allowed.</description>
        </group>
        <group group_id="E2">
          <title>Control Group</title>
          <description>Participants in the control group should be remaining their normal diet</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Assoc.-Prof.Dr. Harald Sourij</name_or_title>
      <organization>Medical University of Graz</organization>
      <phone>+43 316 385 ext 78038</phone>
      <email>norbert.tripolt@medunigraz.at</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

